Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate no safety concern for systemic dosing of the antibody to humans.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the pathology of both cancer and AMD.

The safety tests included cardiovascular studies in Cynomolgus monkeys as well as tests to evaluate the potential of the antibody to elicit the release of cytokines or an Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) reaction. The cardiovascular study included evaluation of the effect of humanized Sphingomab treatment on blood pressure, heart rate, and respiratory rate. The cardiovascular, cytokine release, and ADCC tests with humanized Sphingomab were all negative at doses or concentrations well above those expected to be needed in man to provide an anti-angiogenic action.

The panel of tests also included a pivotal multiple-dosing 28-day study in Cynomolgus monkeys. This study featured intravenous administration of humanized Sphingomab at doses as great as 100 mg/kg every three days for 28 days (10 total doses). Parameters monitored during this study included mortality, body weight, organ weight, clinical observations, ophthalmology, clinical pathology (hematology, clinical chemistry, coagulation, and urinalysis), and immune-phenotyping, both pre-treatment and on day 28 in all animals, and after one, two, three, and four weeks of recovery in a large sub- group of the animals.

No animal deaths occurred during the study. There were also no signific
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  The strongest driver of demand ... increasing elderly population, according to Kalorama Information. The ... the healthcare market research publisher, Global Orthopedic ... risk factors such as obesity is contributing to ... innovative product designs and the trend toward cost ...
(Date:3/4/2015)... DIEGO , March 4, 2015  Tandem Diabetes Care®, ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... of 6,037,500 shares of common stock at a price to ... in full by the underwriters of their option to purchase ... in the offering were offered by Tandem. ...
(Date:3/4/2015)... PARK, Calif. , March 4, 2015 ... company in the emerging field of regenerative medicine, today ... Executive Officer, will ring The Opening Bell ® ... March 5, 2015. Asterias began trading as an NYSE ... "New York Stock Exchange is a trusted partner ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... (OTCQX: DATA), a technology and services company focused on global ... signing of a new client with the award of a ... in aneurysm repair. This six year, US-based study will ... for thoracic aortic aneurysms. , "DATATRAK is excited to work ...
... Healthcare Services, Inc. (NYSE: AHS ), the largest healthcare ... conference call to discuss third quarter results on Thursday, October ... expects to issue an earnings news release on Thursday, October ... p.m. Eastern Time. , A live webcast of the call ...
Cached Medicine Technology:DATATRAK Signs 6 Year Study with New Device Client 2DATATRAK Signs 6 Year Study with New Device Client 3AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
Breaking Medicine News(10 mins):Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... to Iowa from Los Angeles; more ... shipments from Chicago planned, LOS ANGELES, ... Christian relief agency World Vision is dispatching an,initial truckload of emergency ... of affected families., "World Vision will be providing basic items ...
... complain that math homework won,t help them in real life, ... cancer. , In a recent study that combined math and ... (CML) may be cured of the disease with an optimally ... their own immune response. , In the June 20 edition ...
... to pulmonary arterial hypertension, study found , , THURSDAY, ... reduced clinical decline in patients with early-stage pulmonary ... is a progressive disease in which increased pulmonary ... the heart, eventually leading to heart failure and ...
... Pa., June 19 ADVERTISEMENT - The following,statement was ... Topaz &,Kessler, LLP:, Schiffrin Barroway Topaz & Kessler, ... In re Merck & Co. Inc. Securities, Derivative, &,ERISA ... Court for the,District of New Jersey. The Court recently ...
... Fix Competitive Bidding System for DMEPOS,Equipment, ALEXANDRIA, ... of the House Ways & Means Health Subcommittee, ... Reform,Act of 2008. Sens. Max Baucus (D-MT) and ... Senate Finance Committee, have introduced S.3144, the,companion bill. ...
... to Pennsylvania-Grown Tomatoes, HARRISBURG, Pa., June 19 ... been confirmed among Pennsylvania,residents, State Health Secretary Dr. ... to the current multi-state Salmonella outbreak,associated with tomatoes ... April., One case each has been identified ...
Cached Medicine News:Health News:World Vision Responding to Record Flooding in Midwest 2Health News:Math could help cure leukemia 2Health News:Math could help cure leukemia 3Health News:Drug Effective Against Heart-Lung Disorder 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 3Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:Pennsylvania Department of Health Confirms Fifth Salmonella Case Linked to National Outbreak 2
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
Medicine Products: